Blood
Articles in this Issue
Rituximab, cyclophosphamide, mitoxantrone hydrochloride liposome, vincristine, and prednisone (R-CMOP) in elderly patients with newly diagnosed diffuse large B-cell lymphoma: A multicenter, prospective study
Abstract Backgrou nd: Anthracycline-based chemotherapy remains the standard first-line treatment for patients with diffuse large B-cell lymph...
Luspatercept response predictors in lower-risk myelodysplastic syndrome
Abstract Background: Luspatercept is a recombinant fusion protein that targets TGF-β superfamily ligands to enhance late-stage erythropoiesi...
Absolute lymphocyte count (ALC) at apheresis and infusion as a predictor of safety and efficacy for multiple myeloma and B cell malignancies post CAR-T therapy
Abstract Background: Host immunity at time of apheresis and infusion represent distinct periods which may influence response to CAR-T therap...
Outcome and recovery trajectories for intracerebral hemorrhage in adults with primary immune thrombocytopenia
Abstract Introduction Intracerebral hemorrhage (ICH) is a rare but devastating complication of immune thrombocytopenia (ITP). Current knowle...
Increased alemtuzumab exposure correlates with improved responses in heavily pretreated R/R ALL patients: Analysis of the balli-01 trial
Abstract Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized treatment of refractory hematologic cancers, particularly B-cel...
Comparison of lentiviral promoters on the therapeutic efficacy of tri-specific CAR-T cells targeting CD19/CD20/CD22
Abstract Chimeric antigen receptor (CAR) -T cell therapy is a promising approach for cancer treatment, particularly for hematologic malignan...
Pre-existing cytotoxic capacity of CD8+ and CD4+ T cells is a hallmark of richter transformation and favors response to anti-PD-1 therapy
Abstract Immune checkpoint blockade (ICB) therapy has shown promising activity in Richter Transformation (RT), yet the tumor microenvironmen...
Melphalan versus cyclophosphamide combined with fludarabine and low dose total body irradiation (TBI) prior to ptcy-based allogeneic transplantation
Abstract A preparative regimen of fludarabine, cyclophosphamide (Cy) and low dose TBI 200cGy (FC-TBI) followed by post-transplant Cy (PTCy)...
Longitudinal ctdna tracking by low-pass whole-genome sequencing during CD19 CAR-T cell therapy for B-cell lymphomas
Abstract Objective: This study aims to explore the utility of low-pass whole-genome sequencing (LP-WGS) for serial peripheral blood circulat...
Geographic, demographic, and risk factor profiles of acute myeloid and acute lymphoblastic leukemia in the United States: Insights from the global burden of disease study 2021
Abstract Background: Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are aggressive hematologic malignancies with substa...
Protein C exhibits significant differences in plasma levels and tissue expression in inbred mice
Abstract Background:The Protein C (PC) pathway is an essential negative regulator of blood coagulation. Activated Protein C (aPC) downregula...
The impact of additional cytogenetic abnormalities and complex karyotype on outcomes of adult patients with Philadelphia-positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in first complete remission: A study from the ALWP/EBMT
Abstract Background: (Ph+) is the most common cytogenetic abnormality in adults with ALL. Additional chromosomal abnormalities (ACA) are fou...
Initial phase 1b/2 study results with sonrotoclax (BGB-11417) in combination with carfilzomib and dexamethasone in patients with t(11;14)-positive relapsed/refractory multiple myeloma
Abstract Introduction: Multiple myeloma (MM) with t(11;14), present in approximately 16-24% of patients with MM, represents a unique disease...
Implementation of a patient-reported outcome assessment during radiotherapy for mycosis fungoides and other cutaneous lymphomas
Abstract Introduction: Radiotherapy (RT) is often used to manage disease burden and symptoms in patients with cutaneous lymphomas. However,...
Single-cell transcriptomic profiling reveals tumor-intrinsic heterogeneity and immune-microenvironment dynamics in the order trial for mantle-cell lymphoma
Abstract Background: We conducted an open-label, randomized, multicenter trial (NCT06496308) enrolling previously untreated patients with in...
Aplastic anemia in patients admitted to the hospital: Clinical characteristics, risk stratification, and outcomes from a large inpatient care database
Abstract Background Aplastic anemia (AA) is a rare, life-threatening hematologic disorder characterized by pancytopenia and a hypocellular b...
Real-world multicenter outcomes of CD3xCD20 bispecific antibody therapies in patients with central nervous system (CNS) lymphoma
Abstract Introduction: CNS involvement in B-cell non-Hodgkin lymphoma (B-NHL) results in poor outcomes and remains an unmet need. The CD3xCD...
Polatuzumab vedotin, zanubrutinib, rituximab, lenalidomide, and prednisone (Pola-ZR2P) as frontline immunochemotherapy in previously untreated DLBCL patients
Abstract Background: Suboptimal cure rates with frontline therapy and limited treatment tolerance in elderly and frail patients were two maj...
Genome editing for treatment of JAK2 V617F-driven myeloproliferative neoplasms
Abstract Genome editing is a promising new avenue for cancer therapy as it allows for precise inactivation of oncogenic driver mutations. Ho...
In vitro evidence supporting the use of exogenous IL-2 support for allogeneic UCART22 cells to treat heavily pretreated R/R B-ALL patients
Abstract Introduction: Clinical and preclinical studies suggest that exogenous low dose Interleukin-2 (IL-2) administration can significantl...
Real-world outcomes of Mantle Cell Lymphoma in Colombia: A multicenter cohort study
Abstract Introduction: Mantle cell lymphoma (MCL) remains understudied in Latin America, with limited data on clinical p...
Ivosidenib combined with venetoclax and azacitidine for the treatment of newly diagnosed IDH1-mutant Acute Myeloid Leukemia: A prospective, two cohorts, multicenter study
Abstract Background: In 2009, IDH1 mutations (IDH1m) were first described in AML. Over the past 15 years, the adverse impact of IDH1m on pro...
Lower neutrophil counts after hematopoietic stem cell transplant for sickle cell disease patients using donors with duffy-null phenotype
Abstract Background: Individuals with the Duffy null phenotype (red blood cells that lack the Fya and Fyb antigens) have fewer circulating n...
Validation and refinement of the new high-risk multiple myeloma (HRMM) criteria in relapsed or refractory patients treated with BCMA CAR-T.
Abstract Introduction: The consensus definition of high-risk multiple myeloma (HRMM) was recently revised by the International Myeloma Socie...
A discrete choice experiment (DCE) to determine preferences for relapsed-refractory follicular lymphoma (R-R FL) treatment attributes among patients and physicians in the USA
Abstract Background Follicular lymphoma (FL) is an indolent form of non-Hodgkin lymphoma. After initial treatment, patients often relapse or...